- Home
- MRVI
as 12-18-2024 12:39pm EST
Maravai LifeSciences Holdings Inc is a life sciences company. It provides products to enable the development of drug therapies, diagnostics, and novel vaccines and supports research on human diseases. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.
| Founded: | 2020 | Country: | United States |
| Employees: | N/A | City: | SAN DIEGO |
| Market Cap: | 809.2M | IPO Year: | 2020 |
| Target Price: | $10.03 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 11 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $4.28 - $11.56 | Next Earning Date: | 11-07-2024 |
| Revenue: | $276,920,000 | Revenue Growth: | -33.99% |
| Revenue Growth (this year): | -8.41% | Revenue Growth (next year): | 3.41% |
Stock Insider Trading Activity of Maravai LifeSciences Holdings Inc. (MRVI)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| DeFord John A | MRVI | Director | Nov 12 '24 | Buy | $5.75 | 17,500 | $100,625.00 | 70,046 | |
| HULL CARL | MRVI | See Remarks | Nov 11 '24 | Buy | $5.64 | 175,000 | $987,000.00 | 175,000 |
Latest Maravai LifeSciences Holdings Inc. News
MRVI Breaking Stock News: Dive into MRVI Ticker-Specific Updates for Smart Investing
MT Newswires
9 days ago
RBC Lowers Price Target on Maravai Lifesciences Holdings to $11 From $13, Keeps Outperform Rating
GlobeNewswire
13 days ago
Maravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of Directors
MT Newswires
13 days ago
Goldman Sachs Downgrades Maravai Lifesciences to Sell From Neutral, Cuts Price Target to $4.25 From $7
Simply Wall St.
a month ago
Exploring ACNB And 2 More Undervalued Small Caps With Insider Buying In US
MT Newswires
a month ago
Wolfe Research Initiates Maravai Lifesciences at Perform
GlobeNewswire
a month ago
Maravai LifeSciences Announces November 2024 Investor Conference Schedule
Simply Wall St.
a month ago
Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) Just Reported Earnings, And Analysts Cut Their Target Price
TipRanks
a month ago
Maravai Lifesciences price target lowered to $9 from $10 at Baird
Compare MRVI vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRVI Maravai LifeSciences Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.